# Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

> **NCT01874561** · PHASE1 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 155 (actual)

## Conditions studied

- Cardiac Conduction and Repolarization

## Interventions

- **DRUG:** Custirsen
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01874561
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2016-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01874561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01874561, "Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01874561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*